Xilio Therapeutics Reports Revenue Growth Amidst Challenges
I'm PortAI, I can summarize articles.
Xilio Therapeutics Inc. reported Q3 earnings with a significant increase in collaboration and license revenue to $19.1 million from $2.3 million last year. Despite revenue growth, the company faced a net loss of $16.3 million due to increased R&D expenses, which rose to $21 million. The fair value change of common stock warrant liabilities also negatively impacted results. Xilio remains focused on advancing its immuno-oncology therapies and securing additional capital amidst financial sustainability challenges.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments